Free testosterone: what moves it and how to read it

Free testosterone, defined in plain terms

Total testosterone is not uniformly available to tissues. Most circulating testosterone is bound to proteins: approximately 60 percent binds tightly to sex hormone-binding globulin (SHBG) and is considered biologically inactive. A further 38 percent binds loosely to albumin and is potentially available. Only 1 to 3 percent circulates as free testosterone, unbound and immediately accessible to androgen receptors in muscle, brain, bone, and other target tissues.

This distinction matters clinically. A 2018 Endocrine Society clinical practice guideline recommends measuring free testosterone when total testosterone is borderline or when abnormalities in binding proteins are suspected, specifically because total testosterone alone can miss clinically significant androgen deficiency. Research has shown that free testosterone detects occult hypogonadism missed by total testosterone alone. Age-stratified reference data from a 2025 study published in the Journal of Clinical Endocrinology and Metabolism established that directly measured free testosterone declines predictably with age in healthy men, underscoring the importance of age-appropriate interpretation. SHBG is the dominant lever — understanding your SHBG level is the necessary context for interpreting free testosterone.

The levers that shift the free fraction

SHBG: the primary determinant of free fraction (Evidence: Strong)

Sex hormone-binding globulin is the principal determinant of how much free testosterone is available at any given total testosterone level. When SHBG is elevated, a larger proportion of circulating testosterone is sequestered and unavailable to tissues. SHBG rises with aging, liver disease, hyperthyroidism, and caloric restriction; it falls with obesity, insulin resistance, and hypothyroidism. A 2024 meta-analysis in the Annals of Internal Medicine confirmed that lower SHBG levels are independently associated with increased all-cause and cardiovascular mortality in men, establishing SHBG as a marker of metabolic health in its own right, not merely a transport protein. Understanding your SHBG level alongside total testosterone is the necessary context for interpreting free testosterone.

Body composition and visceral adiposity (Evidence: Strong)

Adipose tissue, particularly visceral fat, expresses aromatase, the enzyme that converts testosterone to estradiol. Elevated body fat increases aromatase activity, reducing total testosterone. Simultaneously, obesity suppresses SHBG, which might appear to increase free testosterone, but the net effect of adiposity-driven aromatization and hypothalamic-pituitary suppression is typically a meaningful reduction in both total and free testosterone. Research in Communications Medicine confirms complex metabolic links between testosterone and body composition. Weight loss, particularly through methods that reduce visceral adiposity, is among the most consistently effective interventions for improving testosterone levels in overweight men.

Resistance training and physical activity (Evidence: Moderate)

Resistance exercise acutely raises testosterone in the hours following a session, primarily through reduced SHBG and increased testicular secretion in response to luteinizing hormone (LH) stimulation. Chronic resistance training is associated with higher resting testosterone compared to sedentary controls, though the magnitude of the effect depends on training volume, intensity, and individual variation. Endurance exercise at very high volumes may suppress testosterone through HPA-axis activation; the appropriate balance is toward moderate-to-high intensity resistance work rather than extreme aerobic volume.

Sleep duration and quality (Evidence: Strong)

The majority of daily testosterone secretion occurs during sleep, particularly during slow-wave sleep phases. Studies restricting sleep to five hours or fewer demonstrate reductions in morning testosterone of 10 to 15 percent after one week, with free testosterone declining proportionally. Chronic insufficient sleep is therefore a relevant and modifiable contributor to low androgen levels in otherwise healthy men. Prioritizing seven to nine hours of sleep per night, along with addressing sleep-disordered breathing if present, is supported by this evidence.

Nutritional status (vitamin D and zinc) (Evidence: Moderate for zinc-deficient men; Limited for general population)

Zinc is required for the function of multiple enzymes involved in testosterone biosynthesis and for the proper functioning of androgen receptors. Supplementation in zinc-deficient men has been shown in controlled trials to raise testosterone toward normal levels; however, supplementation in zinc-sufficient individuals does not reliably raise testosterone further. Vitamin D receptors are present in Leydig cells, the testicular cells responsible for testosterone synthesis, and observational data consistently show an association between higher 25-OH vitamin D levels and higher total and free testosterone — though Mendelian randomization studies suggest the relationship is correlational rather than strictly causal in otherwise healthy populations. In men with documented deficiency of either nutrient, correction is a reasonable first step before concluding that testosterone levels are intrinsically impaired.

Stress and cortisol (Evidence: Strong for mechanism; Moderate for intervention)

The hypothalamic-pituitary-adrenal (HPA) axis and the hypothalamic-pituitary-gonadal (HPG) axis are in a reciprocal inhibitory relationship. Chronically elevated cortisol from sustained psychological or physiological stress suppresses GnRH release, which reduces LH and FSH secretion, in turn reducing testicular testosterone production. This mechanism explains testosterone suppression during overtraining, caloric deficit, illness, and chronic psychosocial stress. Research published in the Journal of Clinical Endocrinology and Metabolism demonstrates that low testosterone drives oxidative stress and inflammation, establishing a bidirectional relationship between androgenic status and stress biology.

Evidence-graded levers for supporting free testosterone

Step 1: Weight loss and visceral fat reduction in overweight individuals (Evidence: Strong)

Precondition: Visceral adiposity present (BMI >25 with waist circumference elevations). Adiposity-driven aromatization and hypothalamic-pituitary suppression reduce both total and free testosterone; this step is not applicable where body composition is already healthy. How to know if it moved: Retest free testosterone, total testosterone, and SHBG at 8–12 weeks. If the panel moves in the direction the mechanism predicts — free T rising alongside a reduction in SHBG — the intervention did something.

Step 2: Resistance training, 2–4× weekly (Evidence: Moderate)

Precondition: Sedentary baseline or undertrained relative to fitness age. Chronic resistance training is associated with higher resting testosterone compared to sedentary controls; the effect is most pronounced when starting from a low-activity baseline. Moderate-to-high intensity resistance work is preferred over extreme aerobic volume, which can suppress testosterone through HPA-axis activation. How to know if it moved: Retest free testosterone and SHBG at 8–12 weeks.

Step 3: Sleep optimization — 7–9 hours with attention to sleep-disordered breathing (Evidence: Strong)

Precondition: Documented sleep restriction (fewer than 7 hours per night) or suspected sleep apnea. One week of sleep restricted to five hours or fewer reduces morning testosterone by 10–15 percent, with free testosterone declining proportionally. Addressing sleep-disordered breathing, where present, removes a compounding suppressive factor. How to know if it moved: Retest free testosterone on a morning draw at 8–12 weeks.

Step 4: Zinc assessment and repletion where deficient (Evidence: Moderate for deficient men; not applicable for replete)

Precondition: Serum or plasma zinc confirms deficiency (<70 µg/dL). Supplementation in zinc-deficient men has been shown in controlled trials to raise testosterone toward normal levels; supplementation in zinc-sufficient individuals does not reliably raise testosterone further and can impair copper absorption. Studies demonstrating benefit used supplemental zinc in deficient men over several weeks; the appropriate dose and duration for your situation is a clinical decision. How to know if it moved: Retest free testosterone and serum zinc at 8–12 weeks.

Step 5: Vitamin D assessment and correction where deficient (Evidence: Limited for causation; reasonable as a corrective step)

Precondition: 25-OH vitamin D confirms deficiency (<20 ng/mL). Observational data consistently associate higher vitamin D levels with higher free and total testosterone, but Mendelian randomization studies suggest the relationship is correlational rather than strictly causal in otherwise healthy populations. In men with documented deficiency, correction is a reasonable first step before concluding testosterone levels are intrinsically impaired. How to know if it moved: Retest free testosterone and 25-OH vitamin D at 8–12 weeks.

Anti-patterns when free testosterone reads low

Interpreting total testosterone alone without SHBG or free testosterone

A man with total testosterone in the low-normal range and elevated SHBG may have clinically meaningful free testosterone deficiency. Total testosterone in isolation misses this pattern entirely. Always interpret total testosterone alongside SHBG and, where SHBG is abnormal or total testosterone is borderline, a directly measured free testosterone.

Supplementing zinc without a baseline zinc draw

Zinc supplementation in a zinc-replete man does not raise testosterone. It can impair copper absorption, producing a secondary deficiency. Serum or plasma zinc must confirm deficiency before supplementing — this is not a step to take on the assumption that more zinc is better.

Drawing testosterone in the afternoon

Testosterone follows a diurnal pattern with a peak in the early morning. Afternoon draws can underestimate true levels by 25–30 percent. Standardize to fasted morning draws to make any two results meaningfully comparable; an afternoon result cannot be reliably compared to a morning reference range.

Starting TRT without an LH + FSH + estradiol panel

Testosterone replacement therapy suppresses the HPG axis. Starting without first mapping LH and FSH loses the information needed to distinguish primary (testicular) from secondary (pituitary) causes of low testosterone — information that is critical if fertility preservation matters and that cannot be recovered once suppression begins. Estradiol should also be assessed, as elevated estradiol co-existing with low free testosterone in men with elevated visceral fat is a clinically distinct pattern requiring its own evaluation.

When low free testosterone warrants a clinician visit

Low free testosterone moves from a lifestyle question to a clinical evaluation when symptoms accompany the laboratory finding. Symptoms requiring evaluation include reduced libido, erectile dysfunction, persistent fatigue, reduced muscle mass despite adequate training, depressed mood, and reduced morning erections. These symptoms, when combined with a documented low free testosterone level, meet the Endocrine Society criteria for symptomatic hypogonadism. At that point, the appropriate pathway is an endocrinology consult with LH and FSH measurement to distinguish primary (testicular) from secondary (pituitary) hypogonadism — a distinction that must be made before any intervention is considered.

Day 0 and a paced retest window for free testosterone

Free testosterone measurement alone is insufficient for a complete androgen evaluation. The following companion panel provides the necessary context to interpret what your free testosterone level means and what may be driving it.

• Free testosterone — Primary biomarker; more clinically informative than total testosterone when SHBG is abnormal; age-stratified reference ranges apply
• Total testosterone — Provides the production baseline; free testosterone becomes the critical number when SHBG is abnormal or total testosterone is borderline
• SHBG — The primary determinant of free fraction; always interpret free testosterone in the context of SHBG
• LH — Pituitary signal driving testicular production; distinguishes primary from secondary hypogonadism
• Estradiol — Aromatase converts testosterone to estradiol; elevated estradiol can co-exist with low free testosterone in men with elevated visceral fat

All draws should be taken fasted in the early morning to capture the diurnal peak. On lifestyle interventions, allow 8–12 weeks before retesting; a 3-month cadence is appropriate while optimizing. If the panel moves in the direction the mechanism predicts at Day ~90 — free testosterone rising, SHBG shifting as expected — the change did something.

When low free testosterone needs an endocrinology read

Low free testosterone accompanied by symptoms — reduced libido, erectile dysfunction, persistent fatigue, reduced muscle mass despite adequate training, depressed mood, or reduced morning erections — warrants clinical evaluation rather than further self-directed optimization. These symptoms, combined with a documented low free testosterone level, meet the Endocrine Society criteria for symptomatic hypogonadism. Evaluation should include LH and FSH to distinguish testicular (primary) from pituitary (secondary) causes before any intervention is considered. This is the named clinical pathway: an endocrinology consult for symptomatic hypogonadism workup.

Superpower pairs rigorous lab testing with the context to act on what you find. Learn more about our approach at superpower.com/manifesto.